Plus Therapeutics (PSTV) Price & Analysis

Compare

1,186 Followers

PSTV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.16 - $2.31

Previous CloseN/A

Volume69.06K

Average Volume (3M)8.13M

Market Cap

$41.35M

Enterprise Value$65.90M

Total Cash (Recent Filing)$9.87M

Total Debt (Recent Filing)$40.00K

Price to Earnings (P/E)―

Beta2.21

Next Earnings

Oct 16, 2025

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding99,264,530

10 Day Avg. Volume5,990,124

30 Day Avg. Volume8,132,650

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.59

Enterprise Value/Revenue28.18

Enterprise Value/Gross Profit-106.97

Enterprise Value/Ebitda-3.48

Forecast

1Y Price Target

$3.67

Price Target Upside753.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Analyst OpinionsAnalyst maintains a BUY rating and raises the 12-month price target to $20.50, indicating a belief in significant upside potential due to Plus Therapeutics' clinical progress and market opportunities.

Funding And Financial PositionA $17.6M grant from the Cancer Prevention & Research Institute of Texas and a $50M stock purchase agreement are expected to fund the company into mid-2026.

Product Launch And ExpansionThe upcoming launch of the CNSide platform, a novel diagnostic tool for leptomeningeal metastases, is expected to be a major positive for the stock.

Bears Say

Financial PerformanceThe company reported $1.0M in grant revenues in 1Q25, compared to consensus estimated revenue of $1.5M, and a net loss of $1.19 per share, compared to consensus estimated net loss of $0.25 per share.

Operational CostsAn agreement with an investor for the purchase of up to 17 million shares of stock would help the company cover operational costs associated with the launch of CNSide.

Plus Therapeutics News

Plus Therapeutics announces accreditation, certification for CNSide Diagnostics

CNSide Diagnostics received a certificate of accreditation from CMS for its lab located in Houston, Texas. Following the...

1d ago

PSTV

Plus Therapeutics upgraded to Buy from Hold at D. Boral Capital

D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics (PSTV) to Buy from Hold with a $5 price...

16d ago

PSTV

Plus Therapeutics regains compliance with applicable Nasdaq listing criteria

Plus Therapeutics (PSTV) announced that it received a letter from Nasdaq on August 22, 2025, confirming its compliance...

24d ago

PSTV

Plus Therapeutics Secures Nasdaq Compliance Extension

Plus Therapeutics ( ($PSTV) ) has shared an update. On August 22, 2025, Plus Therapeutics, Inc. received confirmation...

24d ago

PSTV

Plus Therapeutics price target lowered to $3 from $4 at Maxim

Maxim lowered the firm’s price target on Plus Therapeutics (PSTV) to $3 from $4 and keeps a Buy...

1M ago

PSTV

Plus Therapeutics presents results from ReSPECT-LM Phase 1 trial

Plus Therapeutics (PSTV) announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the...

1M ago

PSTV

Optimistic Buy Rating for Plus Therapeutics Driven by Strategic Financial Positioning and Clinical Advancements

Maxim Group analyst Jason McCarthy has maintained their bullish stance on PSTV stock, giving a Buy rating yesterday....

1M ago

PSTV

Plus Therapeutics reports stockholders’ equity in excess of $2.5M

Plus Therapeutics (PSTV) announced it reported stockholders’ equity of $3M and therefore satisfied Nasdaq Listing Rule 5550(b)(1), as...

1M ago

PSTV

Buy Rating for Plus Therapeutics: Strategic Market Launch and Promising Financial Outlook

Sean Lee CFA, an analyst from H.C. Wainwright, maintained the Buy rating on Plus Therapeutics. The associated price...

1M ago

PSTV

Plus Therapeutics Reports Strong Q2 2025 Results

Plus Therapeutics ( ($PSTV) ) has released its Q2 earnings. Here is a breakdown of the information Plus...

1M ago

PSTV

Plus Therapeutics Awaits Nasdaq Compliance Confirmation

Plus Therapeutics ( ($PSTV) ) has provided an update. On June 3, 2025, Plus Therapeutics was notified by...

1M ago

PSTV

Plus Therapeutics presents data from analysis of CNSide CSF Assay

Plus Therapeutics (PSTV) announced positive data from a retrospective analysis of the CNSide Cerebrospinal Fluid, CSF, Assay Platform...

1M ago

PSTV

Plus Therapeutics Granted Continued Nasdaq Listing

An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On June 3, 2025, Plus Therapeutics was...

1M ago

PSTV

Plus Therapeutics Approves Key Proposals at Annual Meeting

An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On August 7, 2025, Plus Therapeutics held...

1M ago

PSTV

PSTV FAQ

What was Plus Therapeutics Inc’s price range in the past 12 months?

Plus Therapeutics Inc lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.

What is Plus Therapeutics Inc’s market cap?

Plus Therapeutics Inc’s market cap is $41.35M.

When is Plus Therapeutics Inc’s upcoming earnings report date?

Plus Therapeutics Inc’s upcoming earnings report date is Oct 16, 2025 which is in 27 days.

How were Plus Therapeutics Inc’s earnings last quarter?

Plus Therapeutics Inc released its earnings results on Aug 14, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.11.

Is Plus Therapeutics Inc overvalued?

According to Wall Street analysts Plus Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Plus Therapeutics Inc pay dividends?

Plus Therapeutics Inc does not currently pay dividends.

What is Plus Therapeutics Inc’s EPS estimate?

Plus Therapeutics Inc’s EPS estimate is -0.02.

How many shares outstanding does Plus Therapeutics Inc have?

Plus Therapeutics Inc has 99,264,530 shares outstanding.

What happened to Plus Therapeutics Inc’s price movement after its last earnings report?

Plus Therapeutics Inc reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 16.667%.

Which hedge fund is a major shareholder of Plus Therapeutics Inc?

Currently, no hedge funds are holding shares in PSTV

Plus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

249.03%

Trailing 12-Months

Asset Growth

-7.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Plus Therapeutics Inc

Plus Therapeutics, Inc. (PSTV) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company is primarily engaged in the development of its lead product candidate, Rhenium-186 NanoLiposome, which is designed for the targeted treatment of brain cancer and other tumors. Plus Therapeutics operates in the biopharmaceutical sector, aiming to provide advanced treatment options that enhance patient outcomes through novel delivery mechanisms and formulations.

Plus Therapeutics (PSTV) Earnings & Revenues

Historic Earnings Reports

PSTV Stock 12 Month Forecast

Average Price Target

$3.67

▲(753.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,0.7815384615384615,1.133076923076923,1.4846153846153847,1.8361538461538462,2.187692307692308,2.5392307692307696,2.8907692307692314,3.242307692307693,3.593846153846154,3.945384615384616,4.296923076923077,4.648461538461539,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,0.6792307692307692,0.9284615384615384,1.1776923076923076,1.4269230769230767,1.6761538461538459,1.9253846153846153,2.1746153846153846,2.4238461538461538,2.673076923076923,2.922307692307692,3.171538461538461,3.420769230769231,{"y":3.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,0.6276923076923077,0.8253846153846154,1.023076923076923,1.2207692307692306,1.4184615384615382,1.616153846153846,1.8138461538461537,2.0115384615384615,2.209230769230769,2.4069230769230767,2.6046153846153843,2.8023076923076924,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.72,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.43,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >